CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |
| Frazier Life Sciences Management, L.P. | 1,589,931 | $47,284,548 | 3.14% |
| Ikarian Capital, LLC | 792,920 | $23,581,441 | 2.84% |
| Novo Holdings A/S | 1,100,000 | $32,714,000 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 220,000 | $6,542,800 | 1.98% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 5,132,287 | $152,634,215 | 1.98% |
| Cormorant Asset Management, LP | 1,101,904 | $32,770,625 | 1.91% |
| ACUTA CAPITAL PARTNERS, LLC | 94,000 | $2,795,560 | 1.87% |
| Orbimed Advisors | 2,896,074 | $86,129,241 | 1.83% |
| COMMODORE CAPITAL LP | 500,000 | $14,870,000 | 1.74% |
| Ikarian Capital, LLC | 4,543 | $13,510,882 | 1.62% |
External links
This page lists CRINETICS PHARMACEUTICALS IN's shareholders in Q3 2023. To view CRINETICS PHARMACEUTICALS IN's shareholder history, click here.